Gene:
NT5C2
5'-nucleotidase, cytosolic II

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs11191561 104869531C>G, 176-3068G>C, 55673995C>G
C > G
Intronic
No VIP available CA VA
rs11598702 104897985T>C, 175+1178A>G, 55702449T>C
T > C
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  purine 5' nucleotidase
Alternate Symbols:  GMP; PNT5; cN-II
PharmGKB Accession Id: PA31801

Details

Cytogenetic Location: chr10 : q24.32 - q24.33
GP mRNA Boundary: chr10 : 104845940 - 104953056
GP Gene Boundary: chr10 : 104842940 - 104963056
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Deoxyribonucleotide salvage - (Reactome via Pathway Interaction Database)
  2. Guanine formation - (Reactome via Pathway Interaction Database)
  3. Hydrolysis of cytosolic nucleoside 5'-monophosphates by 5'-nucleotidase cytosolic II - (Reactome via Pathway Interaction Database)
  4. Inosine formation - (Reactome via Pathway Interaction Database)
  5. Ribonucleotide salvage - (Reactome via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
didanosine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
gemcitabine

Curated Information ?

Publications related to NT5C2: 8

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. British journal of cancer. 2014. Khatri A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013. Vispo Eugenia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics. 2012. Mitra Amit K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. The pharmacogenomics journal. 2010. Toffalorio F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009. Hartford Christine M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome. Leukemia research. 2007. Suzuki Keijiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica. 2005. Galmarini Carlos María, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2005. Sève Pascal, et al. PubMed

LinkOuts

Entrez Gene:
22978
OMIM:
600417
UCSC Genome Browser:
NM_012229
RefSeq RNA:
NM_001134373
NM_012229
RefSeq Protein:
NP_001127845
NP_036361
RefSeq DNA:
AC_000053
AC_000142
NC_000010
NT_030059
NW_001838006
NW_924884
HuGE:
NT5C2
Comparative Toxicogenomics Database:
22978
ModBase:
P49902
HumanCyc Gene:
HS01216
HGNC:
8022

Common Searches